Studies of SARS-CoV-2 NSP1 and Envelope Protein
March 11, 2021
- March 11, 2021
- Organized By:
About the Speaker:
Marli Azevedo, Ph.D.
Research Biologist, Division of Microbiology
National Center for Toxicological Research (NCTR)
Dr. Marli Azevedo studied pharmacy and clinical biochemistry at the College of Pharmacy, Brazil. She earned a Master of Science in tropical medicine with a focus in virology studying diarrheal diseases affecting HIV patients. She earned a Ph.D. in virus immunology at The Ohio State University in 2005, focusing in vaccine design and enteric virus pathogenesis. From 2005 to 2007, she trained at The Ohio State University as a postdoctoral fellow. In 2007, she attained an academic position as a research scientist and adjunct assistant professor at Food Animal Health Research Program at The Ohio State University. In 2009, she joined the Division of Microbiology at NCTR.
About the Presentation:
To elucidate COVID-19 pathogenesis and develop a successful treatment will require a comprehensive understanding of all SARS-CoV-2 viral proteins. The aim of this study is to understand the role of NSP1 and envelope protein in disease pathogenesis. NSP1 and envelope protein were expressed in HEK293T cells. Induction of high level of NSP1 expression coincided with higher cell death, while under high levels of envelope and nucleocapsid proteins expression, cells remained healthy. Future studies will further explore the role of SARS-CoV-2 NSP1 and envelope protein on intracellular calcium modulation.
- Describe the SARS-CoV-2 genome organization and its comparison with other Human Coronaviruses.
- Give a brief overview of SARS-CoV-2 replication cycle.
- Give a brief overview of SARS-CoV-2 non-structural proteins and their known functions.
- Provide an in depth overview of NSP1 and envelope protein functions.
- Describe the effects of NSP1, envelope protein and nucleocapsid expression in HEK293T cells.
- Explain the role of NSP1 and envelope protein on the intracellular calcium modulation.
|Activity Outline FDA Grand Rounds: March 11, 2021||pdf (222.31 KB)|